Abstract
Despite the advances in immunosuppressive therapy over the past 10 years, acute and recurrent cardiac allograft rejection remain significant problems. Although a number of immunosuppressive drugs and techniques are under development, few have progressed into clinical trials. Two novel agents, tacrolimus and mycophenolate mofetil, have recently undergone trials in liver, kidney and most recently, cardiac transplantation. Both agents are potent immunosuppressive agents, with quite different mechanisms of action and different side-effect profiles. Although the clinical trials information is currently limited, these drugs will likely play significant roles in the armamentarium of cardiac transplant immunosuppression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
